Medicines by Type Industry News & Blogs

Industry News & Blogs

Abbott Receives Positive Opinion for HUMIRA® in Ulcerative Colitis from EMA's CHMP: February 17,
www.abbott.com | 6 hours 36 minutes ago
Abbott Receives Positive Opinion for HUMIRA® in Ulcerative Colitis from EMA's CHMP

Popular Colorectal Cancer Drug May Cause Permanent Nerve Damage - 09/27/2011
www.hopkinsmedicine.org | 6 hours 48 minutes ago
Oxaliplatin, a platinum-based anticancer drug that’s made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends. The chemotherapy side effect, described by Johns Hopkins researchers in the

Evidence lacking to guide analgesic use in sciatica | 6minutes
www.6minutes.com.au | Feb 16, 2012
Very little evidence is available to guide analgesic choices by GPs for patients with sciatica, according to Australian researchers.

ResearchMoz: Vaccine Production Market (Trends, Techniques, Key Players, Spending Estimates and
www.sys-con.com | Feb 16, 2012
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.

Roche Warns of Counterfeit Avastin in the U S
www.biospace.com | Feb 15, 2012
The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials of the product that have been

Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020 | PRLog
www.prlog.org | Feb 15, 2012
Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020. The Global Type 2 Diabetes Therapeutics Market was worth $23.7 Billion in 2011, Driven by the Growth in the Patient Volume and Annual Cost of Type 2 Diabetes Therapy - PR11799503

Counterfeit Drugs | Roche Warns of Counterfeit Cancer Drug in US | Pharmaceutical Manufacturing
www.pharmamanufacturing.com | Feb 15, 2012
The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials of the product that have been distributed in the U.S.

Vitamin D therapy does not improve certain cardiac measures for patients with chronic kidney disease
www.eurekalert.org | Feb 14, 2012
Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the Feb. 15 issue of JAMA.

Optimer Pharma: 2 Potentially Potent Drugs In The Pipeline - Seeking Alpha
seekingalpha.com | Feb 14, 2012
< strong > By < a href='http://seekingalpha.com/author/Scott-Matusow' > Scott Matusow < /a > : < /strong > < p > The following stock was mentioned on Jim Cramer's last Mad Money show on CNBC by a caller recommending it. Let's see if the company has what it takes to be a long-term winner; < /p > < p

Infection risk not increased with alemtuzumab : The Lancet Oncology
www.thelancet.com | Feb 13, 2012
Infection risk not increased with alemtuzumab. By - Bryant Furlow